ClinConnect ClinConnect Logo
Search / Trial NCT03127631

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients

Launched by MCMASTER UNIVERSITY · Apr 20, 2017

Trial Information

Current as of August 20, 2025

Recruiting

Keywords

Androgen Deprivation Therapy

ClinConnect Summary

The RADICAL PC clinical trial is studying how to improve the heart health and lifestyle of men who have recently been diagnosed with prostate cancer. This trial aims to help patients manage not just their prostate cancer but also any risks related to heart disease and other lifestyle factors. If you are a man diagnosed with prostate cancer within the past year, or if you have started treatment for it recently, you may be eligible to participate.

In this study, researchers will look for ways to support men in making healthy changes that could benefit both their cancer treatment and overall well-being. To join, participants need to be 45 years or older and must be willing to provide consent to be part of the study. Those who have certain heart conditions or are already receiving specific treatments may not be able to participate in all parts of the trial. If you decide to take part, you can expect to work closely with healthcare professionals who will guide you through the process and help you make positive lifestyle changes.

Gender

MALE

Eligibility criteria

  • Inclusion Criteria:
  • 1. A man with a diagnosis of prostate cancer that is either:
  • new (i.e. the diagnosis was made within 1 year of the enrolment visit) or
  • treated with Androgen Deprivation Therapy for the first time within 6 months prior to the enrolment visit, or
  • to be treated with Androgen Deprivation Therapy for the first time within 1 month after the enrolment visit
  • Exclusion Criteria:
  • 1. Patients will be excluded if they fulfill any of the following:
  • 1. are unwilling to provide consent or
  • 2. are \<45 years of age, or
  • 3. prostate cancer was found incidentally following cystectomy for bladder cancer
  • 2. Patients will be eligible for RADICAL PC1, but will not be eligible for RADICAL PC2 if they:
  • 1. see a cardiologist every year, or
  • 2. both take a statin and have systolic blood pressure ≤130mmHg

About Mcmaster University

McMaster University, a leading research institution located in Hamilton, Ontario, Canada, is renowned for its innovative approach to education and its commitment to advancing healthcare through rigorous clinical research. The university's diverse research programs are supported by a multidisciplinary team of experts dedicated to improving patient outcomes and public health. With a strong emphasis on evidence-based medicine, McMaster University actively engages in clinical trials that explore new therapies, interventions, and health technologies, fostering collaboration among researchers, healthcare professionals, and industry partners to translate findings into real-world applications.

Locations

Kansas City, Kansas, United States

Adelaide, South Australia, Australia

Westmead, New South Wales, Australia

Vancouver, British Columbia, Canada

Toronto, Ontario, Canada

Montreal, Quebec, Canada

Ottawa, Ontario, Canada

Hamilton, Ontario, Canada

Waratah, New South Wales, Australia

Adelaide, South Australia, Australia

London, Ontario, Canada

Porto Alegre, Rio Grande Do Sul, Brazil

Petach Tikva, , Israel

Montréal, Quebec, Canada

Floridablanca, Santander, Colombia

Istanbul, , Turkey

São José Do Rio Preto, São Paulo, Brazil

Augusta, Georgia, United States

São José Do Rio Preto, , Brazil

Brampton, Ontario, Canada

Quebec City, Quebec, Canada

Ijuí, Rio Grande Do Sul, Brazil

Hamilton, Ontario, Canada

Kingston, Ontario, Canada

Kitchener, Ontario, Canada

London, Ontario, Canada

Niagara, Ontario, Canada

Toronto, Ontario, Canada

Montreal, Quebec, Canada

Montréal, Quebec, Canada

Belo Horizonte, Minas Gerais, Brazil

São Paulo, , Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

Bogotá, Cundinamarca, Colombia

Votuporanga, São Paulo, Brazil

Uberaba, Minas Gerais, Brazil

Campina Grande Do Sul, Paraná, Brazil

Botucatu, São Paulo, Brazil

Jaú, São Paulo, Brazil

São Paulo, , Brazil

São Paulo, , Brazil

São Paulo, , Brazil

São Paulo, , Brazil

São Paulo, , Brazil

Sherbrooke, Quebec, Canada

Holon, , Israel

Tel Aviv, , Israel

Votuporanga, , Brazil

Rio De Janeiro, , Brazil

Brasilia, Df, Brazil

Campo Largo, Paraná, Brazil

Curitiba, Paraná, Brazil

Recife, Pernambuco, Brazil

Porto Alegre, Rio Grande Do Sul, Brazil

Bragança Paulista, São Paulo, Brazil

São Paulo, , Brazil

São Paulo, , Brazil

Cali, Valle Del Cauca, Colombia

Barueri, Sao Paulo, Brazil

Campina Grande Do Sul, , Brazil

Campo Largo, , Brazil

Curitiba, , Brazil

Botucatu, , Brazil

Bragança Paulista, , Brazil

Jaú, , Brazil

Patients applied

0 patients applied

Trial Officials

Dr. Darryl Leong, MBBs,MPH,PhD,FRACP,FESC

Study Director

McMaster University

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials